The Liquid Biopsy Market is undergoing significant transformation as advances in molecular biology, sequencing, and diagnostic technologies improve the detection and analysis of disease-related biomarkers. Liquid biopsy offers a minimally invasive alternative or complement to conventional tissue-based testing by examining circulating tumor DNA, circulating tumor cells, and other biomarkers in fluids such as blood and urine.

WiseGuyReports states that the global market was valued at USD 8.8 billion in 2024 and is expected to reach USD 29.7 billion by 2035, increasing from USD 9.9 billion in 2025 at a CAGR of 11.6%. The growth outlook reflects increasing demand for non-invasive diagnostics, rising cancer prevalence, technological advancement, and the broader adoption of precision medicine.

Next-generation sequencing is one of the major technologies supporting market development. NGS enables simultaneous analysis of multiple genetic targets and can provide detailed molecular information from relatively small biological samples. Digital PCR is another important technology because of its ability to detect low levels of genetic material with high analytical sensitivity. Together, these technologies are helping expand the potential of liquid biopsy in cancer monitoring and molecular profiling.

The growing importance of circulating tumor DNA is particularly notable. ctDNA can provide information about genetic alterations associated with tumors and may be useful for assessing treatment response and detecting minimal residual disease. Such capabilities support a more dynamic approach to cancer management because testing can potentially be repeated during different stages of treatment.

Artificial intelligence and advanced data analytics are also creating opportunities within the market. Liquid biopsy generates complex molecular datasets that can require sophisticated computational methods for interpretation. AI-supported analysis may help identify patterns within genomic information and contribute to more individualized treatment strategies. WiseGuyReports specifically highlights AI-driven analytics as an opportunity for stakeholders seeking to enhance liquid biopsy interpretation.

The market is segmented across applications including oncology, prenatal testing, infectious diseases, and transplantation. Blood remains an important sample type because it is comparatively easy to collect and supports repeated testing. Diagnostic laboratories, hospitals, and research institutions are among the key end users.

As technology continues to improve sensitivity, specificity, and data interpretation, liquid biopsy is likely to gain broader clinical relevance. Continued research, strategic collaborations, and expanding applications could further strengthen the market's role in precision diagnostics and personalized medicine over the coming years.